Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Products under Development by Stage of Development | 8 | 1 |
| RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Products under Development by Therapy Area | 9 | 1 |
| RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Products under Development by Indication | 10 | 2 |
| RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Products under Development by Companies | 14 | 4 |
| RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Therapeutics Assessment | 18 | 5 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 1 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 1 |
| RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Companies Involved in Therapeutics Development | 23 | 6 |
| ArQule, Inc. | 23 | 1 |
| AstraZeneca Plc | 24 | 1 |
| Cipher Pharmaceuticals Inc. | 25 | 1 |
| Merck &Co., Inc. | 26 | 2 |
| Novartis AG | 28 | 1 |
| RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Drug Profiles | 29 | 14 |
| ARQ-092 Drug Profile | 29 | 3 |
| AZD-5363 Drug Profile | 32 | 2 |
| ISC-4 Drug Profile | 34 | 1 |
| JRP-890 Drug Profile | 35 | 1 |
| MK-2206 Drug Profile | 36 | 3 |
| MK-2206 + selumetinib sulfate Drug Profile | 39 | 1 |
| trametinib dimethyl sulfoxide + uprosertib Drug Profile | 40 | 2 |
| uprosertib Drug Profile | 42 | 1 |
| RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Dormant Projects | 43 | 3 |
| RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Featured News &Press Releases | 46 | 11 |
| Jan 28, 2016: ArQule Provides Update on ARQ 092 | 46 | 1 |
| Nov 17, 2015: ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092 | 46 | 2 |
| Nov 08, 2015: BIND Presents Data on MK-2206, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | 48 | 1 |
| Oct 26, 2015: BIND Therapeutics' Presentation at Upcoming AACR-NCI-EORTC Conference Reinforce Potential of Accurin Platform to Develop Best-in-Class Therapeutics | 49 | 1 |
| Oct 15, 2015: ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 in Oncology | 49 | 1 |
| Sep 28, 2015: ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference | 50 | 1 |
| Nov 13, 2014: ArQule Announces Data Presentations on ARQ 092 at 26th EORTC-NCI-AACR Symposium | 51 | 1 |
| Nov 11, 2014: ArQule Announces Collaboration with NIH for Clinical Development of ARQ 092 in Proteus Syndrome | 52 | 1 |
| Oct 21, 2013: New Drug Combinations May Benefit Patients With Pancreatic Cancer | 52 | 1 |
| Apr 09, 2013: ArQule s New AKT Pathway Inhibitor, ARQ 092, Demonstrates Safety, Target Inhibition in Phase I Trial | 53 | 1 |
| Apr 07, 2013: AstraZeneca's AKT Inhibitor AZD5363 Well Tolerated, Yieldes Partial Response In Patients With Advanced Solid Tumors, Phase I Study Finds | 54 | 1 |
| Nov 10, 2011: Daiichi Sankyo To License ARQ 092 From ArQule, The First New Compound Resulting From The Companies Joint AKIP Research Collaboration | 55 | 1 |
| Apr 12, 2011: Astex Announces Commencement Of Phase I Study For AZD5363 In Anti-Cancer Collaboration With AstraZeneca | 56 | 1 |
| Jun 01, 2009: AstraZeneca and Merck &Co., Inc. Form Pioneering Collaboration to Investigate Novel Combination Anticancer Regimen | 56 | 1 |
| Appendix | 57 | 2 |
| Methodology | 57 | 1 |
| Coverage | 57 | 1 |
| Secondary Research | 57 | 1 |
| Primary Research | 57 | 1 |
| Expert Panel Validation | 57 | 1 |
| Contact Us | 57 | 1 |
| Disclaimer | 58 | 1 |